



**Date: 12<sup>th</sup> February, 2024**

**BSE Limited**

The Compliance Department of Corporate Services,  
14th Floor, P.J. Towers,  
Dalal Street,  
Mumbai - 400 001.

**BSE Scrip Code : 531592**

**Subject : Outcome of Board Meeting held on Monday, 12<sup>th</sup> February, 2024.**

Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Monday, 12<sup>th</sup> February, 2024 has:

1. Considered and Approved and taken on records the Un-Audited Financial Results along with Limited Review Report for the Quarter and Nine months ended 31<sup>st</sup> December, 2023 prepared in terms of IND-AS, pursuant to Regulation 33 of (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on your records.

The Board Meeting commenced at 04.00 P.M. (IST) and concluded at 04.19 P.M. (IST)

Thanking You,

Yours Faithfully,

For GENPHARMASEC LIMITED



**Ulhas Deosthale**  
Whole Time Director  
DIN: 09215291





# Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: 201, Mukund Palace, New Golden Nest Road, Bhayander ( East), Dist – Thane, Maharashtra- 401105

Mob 9029326651, Email: caabhishek2012@gmail.com

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
Board of Directors of  
GENPHARMASEC LIMITED  
(Formerly Known as 'Generic pharmasec Limited')

We have reviewed the accompanying statement of unaudited financial results of GENPHARMASEC LIMITED (Formerly Known as 'Generic pharmasec Limited') for the quarter ended 31<sup>st</sup> December, 2023 and year to date results for the period from 1<sup>st</sup> April, 2023 to 31<sup>st</sup> December, 2023 ('the Statement') attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation").

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rule, 2015, as amended and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Indian accounting Standards ('Ind AS') prescribed under s.133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Abhishek S Tiwari & Associates  
Chartered Accountants



Abhishek Tiwari  
Partner  
M.No.155947

Place of signature: Mumbai

Date: 12.02.2024

UDIN: **24155947BKCAUM7614**

**GENPHARMASEC LIMITED**  
(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)

CIN No. L24231MH1992PLC323914

Registered Office:-104 & 105 1st Floor Gundecha Industrial Premises Co-op Soc. Ltd.Akurli Road Kandivali East Mumbai 400101  
Statement of Standalone Unaudited Financial Results for the Quarter Ended on 31st December,2023

(Rs. In Lakhs)

| Particulars  | Quarter Ended   |                 |                 | Nine Months ended |                 | Year Ended        |
|--|-----------------|-----------------|-----------------|-------------------|-----------------|-------------------|
|  | 31.12.2023      | 30.09.2023      | 31.12.2022      | 31.12.2023        | 31.12.2022      | 31.03.2023        |
|  | (Unaudited)     | (Unaudited)     | (Unaudited)     | (Unaudited)       | (Unaudited)     | (Audited)         |
| <b>1 Revenue from Operations</b>   | 638.45          | 785.86          | 640.56          | 2,020.72          | 1,929.92        | 2,551.57          |
| <b>2 Other Income</b>  | 14.25           | 15.23           | 1.86            | 40.67             | 4.21            | 10.01             |
| <b>3 Total Revenue (1 + 2)</b>   | <b>652.70</b>   | <b>801.09</b>   | <b>642.43</b>   | <b>2,061.39</b>   | <b>1,934.14</b> | <b>2,561.58</b>   |
| <b>4 Expenses</b>  |                 |                 |                 |                   |                 |                   |
| Purchase of stock-in-trade   | 393.96          | 560.95          | 724.40          | 1,570.87          | 1,688.26        | 2,318.40          |
| Changes in inventories of finished goods, work-in-progress and stock-in-trade  | 104.62          | 102.51          | (143.86)        | 33.92             | 120.59          | 21.34             |
| Employee benefits expense  | 23.46           | 16.96           | 18.36           | 60.21             | 36.78           | 53.67             |
| Depreciation and amortisation expense  | 0.47            | 0.08            | 0.51            | 1.25              | 1.36            | 1.97              |
| Finance Cost   | 12.45           | 6.50            | -               | 25.24             | -               | 5.60              |
| Other expenses   | 114.76          | 109.55          | 19.45           | 355.90            | 79.21           | 132.45            |
| <b>Total expenses</b>  | <b>649.72</b>   | <b>796.54</b>   | <b>618.86</b>   | <b>2,047.39</b>   | <b>1,926.21</b> | <b>2,533.42</b>   |
| <b>5 Profit/(Loss) Before Exceptional item and Tax (3-4)</b>   | <b>2.98</b>     | <b>4.55</b>     | <b>23.56</b>    | <b>13.99</b>      | <b>7.92</b>     | <b>28.16</b>      |
| <b>6 Exceptional items</b>   | -               | -               | -               | -                 | -               | -                 |
| <b>7 Profit/(Loss) Before Tax (5-6)</b>  | <b>2.98</b>     | <b>4.55</b>     | <b>23.56</b>    | <b>13.99</b>      | <b>7.92</b>     | <b>28.16</b>      |
| <b>8 Tax expense</b>   |                 |                 |                 |                   |                 |                   |
| (1) Current Tax  | -               | -               | -               | -                 | -               | -                 |
| (2) Deferred Tax Expenses/(Credit)   | 3.39            | (3.75)          | -               | (4.20)            | -               | 84.32             |
| (3) Earlier Year Tax   | (0.03)          | -               | -               | (0.03)            | -               | -                 |
| <b>9 Profit / (Loss) from continuing operations (7 - 8)</b>  | <b>6.34</b>     | <b>0.79</b>     | <b>23.56</b>    | <b>9.76</b>       | <b>7.92</b>     | <b>112.48</b>     |
| <b>10 Profit / (Loss) from discontinuing operations</b>  | -               | -               | -               | -                 | -               | -                 |
| <b>11 Tax expense of discontinuing operations</b>  | -               | -               | -               | -                 | -               | -                 |
| <b>12 Profit/(loss) from Discontinuing operations (after tax)</b>  | -               | -               | -               | -                 | -               | -                 |
| <b>13 Profit (Loss) for the period (9+12)</b>  | <b>6.34</b>     | <b>0.79</b>     | <b>23.56</b>    | <b>9.76</b>       | <b>7.92</b>     | <b>112.48</b>     |
| <b>14 Other Comprehensive income;</b>  |                 |                 |                 |                   |                 |                   |
| <b>A (i) Items that will not be reclassified to profit or loss</b>   | 28.87           | (3.45)          | (11.16)         | 103.75            | (101.91)        | (116.40)          |
| (ii) Income tax relating to items that will not be reclassified to profit or loss  | -               | -               | -               | -                 | -               | -                 |
| <b>B (i) Items that will be reclassified to profit or loss</b>   | -               | -               | -               | -                 | -               | -                 |
| (ii) Income tax relating to items that will be reclassified to profit or loss  | -               | -               | -               | -                 | -               | -                 |
| <b>15 Total Comprehensive Income for the period (13+14) (Comprising profit/ (loss) and other Comprehensive Income for the period</b> | <b>35.21</b>    | <b>(2.66)</b>   | <b>12.41</b>    | <b>113.51</b>     | <b>(93.99)</b>  | <b>(3.92)</b>     |
| <b>16 Paid-up Equity Share Capital (Face value of equity share is Rs.1/- each)</b>   | <b>2,768.60</b> | <b>2,768.60</b> | <b>2,768.60</b> | <b>2,768.60</b>   | <b>2,768.60</b> | <b>2,768.60</b>   |
| <b>17 Other Equity</b>   |                 |                 |                 |                   |                 | <b>(1,235.56)</b> |
| <b>18 Earnings per equity share (for discontinued &amp; continuing operations) of face value of Rs. 10 each</b>                      |                 |                 |                 |                   |                 |                   |
| (a) Basic  | 0.00            | 0.00            | 0.01            | 0.00              | 0.00            | 0.04              |
| (b) Diluted  | 0.00            | 0.00            | 0.01            | 0.00              | 0.00            | 0.04              |

Notes:

1 The Financial result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 12th February, 2024.

2 The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.

3 The Financial results for the quarter ended on 31st December, 2023 have been subjected to a "Limited Review" by the statutory auditors of the Company. The Limited review report does not contain any qualification. The Limited review report will be filed with the stock Exchange and will also be available on Company's website www.genpharmasec.com.

4 Segment Reporting has been annexed in Annexure 1.

5 The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors.

6 The company has outstanding loan of Rs. 41.96 Lacs as on 31.12.23, which will be expected to be recovered on or before 30th September, 2023. The Company has made ECI provision Rs. 10.49 Lacs in this respect included under the head 'Other Expenses' for the quarter ended 31.12.2023.

7 The Name of the company has been changed from Generic Pharmasec Limited to Genpharmasec Limited w.e.f 25th October,2021.

8 The Company is opting for alternative tax regime section of 115BAA of Income Tax Act, 1961 from FY 2022-23 onwards for filing of Income Tax Return . Hence, MAT credit of Rs.26.87 Lacs has been lapsed.

9 The Company has recognised the Deferred Tax Assets of Rs. 73.19 Lacs on Carried forward Loss of Rs.319.89 Lacs as per income tax records on the bases of management estimate of virtual certainty of Profit in future.

10 The company has incorporated a subsidiary namely, M/s Genpharmasec Middle East DMCC in Dubai vide Certificate of Incorporation No. DMCC197026 and obtained a Trading License No. DMCC - 887983 dated 13th July 2023 for trading of medical Surgical Equipment, Instruments, Articles, Medical Gas and Food Supplements. The company stake is 52% In the said subsidiary. However, the company is in the process of transferring the subscription amount and completing the bank formalities as required.

11 During the quarter ended 31st December, 2023; the company made investment in M/s. Derron Healthcare Pvt Ltd, (DHPL) as detailed hereunder:

The Company has entered into an Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement' (SSSA) on the same day to and agreed to induct Rs. 5 Crores into DHPL and in turn, DHPL will allot 13,84,542 shares to the Company.

In this Quarter, the Company made payment of Rs. 1,20,37,655/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 3,33,333 shares. The Company has also inducted Rs. 2 crore in DHPL for subscription of 5,53,817 shares. These payments represent part-payment towards total acquisition of 70% shareholding in DHPL and additional shareholding as envisaged in SSSA.

The total acquisition is to be completed by 19th September 2024. However, M/s. Genpharmasec Ltd, the company, will gain 'controlling interest' only after complete execution of respective SPA and SSA.

12 The company has incorporated a new wholly owned subsidiary namely M/s. Clinigenome India Pvt Ltd' to expand the business activities on 29.01.2024

For and on behalf of the Board of  
Genpharmasec Limited  
(Formerly known as Generic Pharmasec Ltd)

*U. Narayan Deosthale*

(Ulhas Narayan Deosthale)  
Whole Time Director  
DIN:09215291



PLACE : MUMBAI  
Date :12.02.2024

| <b>GENPHARMASEC LIMITED</b><br><b>(FORMERLY KNOWN AS GENERIC PHARMASEC LIMITED)</b><br><b>CIN No. L24231MH1992PLC323914</b><br>Registered Office: 104 & 105 1st Floor Gundecha Industrial Premises Co-op Soc. Ltd. Akurli Road Kandivali East Mumbai 400101<br>"ANNEXURE - I"<br><b>Statement of Segment-wise Unaudited Revenue, Results, Assets and Liabilities for the Quarter</b><br><b>(Rs. In Lakhs)</b> |                 |                 |                 |                   |                 |                 |
|---|-----------------|-----------------|-----------------|-------------------|-----------------|-----------------|
| Particulars   | Quarter Ended   |                 |                 | Nine months ended |                 | Year Ended      |
|   | 31.12.2023      | 30.09.2023      | 31.12.2022      | 31.12.2023        | 31.12.2022      | 30.03.2023      |
|   | (Unaudited)     | (Unaudited)     | (Unaudited)     | (Unaudited)       | (Unaudited)     | (Audited)       |
| <b>Segment Revenue</b>  |                 |                 |                 |                   |                 |                 |
| Diagnostic Equipments   | 638.45          | 785.86          | 640.56          | 2,020.72          | 1,906.69        | 2,528.34        |
| Trading in Securities   | -               | -               | -               | -                 | 23.23           | 23.23           |
| <b>Total Revenue</b>  | <b>638.45</b>   | <b>785.86</b>   | <b>640.57</b>   | <b>2,020.72</b>   | <b>1,929.92</b> | <b>2,551.57</b> |
| <b>Segment Results (Profit before tax and interest)</b>   |                 |                 |                 |                   |                 |                 |
| Pharmaceuticals   | (33.42)         | 43.27           | 54.07           | 94.22             | 138.57          | 195.80          |
| Trading in Securities   | 21.51           | (2.54)          | (8.30)          | 77.18             | (86.24)         | (94.53)         |
| <b>Total</b>  | <b>(11.92)</b>  | <b>40.73</b>    | <b>45.78</b>    | <b>171.40</b>     | <b>52.33</b>    | <b>101.27</b>   |
| <b>Less</b>   |                 |                 |                 |                   |                 |                 |
| (i) Unallocated Finance Cost  | -               | -               | -               | -                 | -               | -               |
| (ii) Other unallocable expenditure net of unallocable income  | 14.90           | (36.18)         | (22.11)         | (157.41)          | 44.41           | (73.11)         |
| (iii) Inter Segment Eliminations  | -               | -               | -               | -                 | -               | -               |
| <b>Profit Before Tax</b>  | <b>2.98</b>     | <b>4.55</b>     | <b>23.66</b>    | <b>13.99</b>      | <b>7.92</b>     | <b>28.16</b>    |
| <b>Segment Assets</b>   |                 |                 |                 |                   |                 |                 |
| Pharmaceuticals   | 1,068.62        | 1,574.73        | 1,405.31        | 1,068.62          | 1,405.31        | 1,483.52        |
| Trading in Securities   | 148.94          | 126.58          | 79.20           | 148.94            | 79.20           | 70.93           |
| Un-Allocated  | 1,083.17        | 341.58          | 299.63          | 1,083.17          | 299.63          | 433.08          |
| <b>Total</b>  | <b>2300.72</b>  | <b>2,042.89</b> | <b>1,784.14</b> | <b>2,300.72</b>   | <b>1,784.15</b> | <b>1,987.54</b> |
| <b>Segment Liabilities</b>  |                 |                 |                 |                   |                 |                 |
| Pharmaceuticals   | 84.77           | 182.35          | 336.29          | 84.77             | 336.29          | 137.72          |
| Trading in Securities   | -               | -               | -               | -                 | -               | -               |
| Un-Allocated  | 2,215.95        | 1,860.54        | 1,447.85        | 2,215.95          | 1,447.85        | 1,849.81        |
| <b>Total</b>  | <b>2,300.72</b> | <b>2,042.89</b> | <b>1,784.14</b> | <b>2,300.72</b>   | <b>1,784.14</b> | <b>1,987.54</b> |
|   | -               | -               | -               | -                 | -               | -               |

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND

or and on behalf of the Board  
Genpharmasec Limited  
Formerly known as Generic Pharmasec Ltd)

*U. Narayan Deosthale*

(Ulhas Narayan Deosthale)  
Whole Time Director  
DIN:09215291



PLACE : MUMBAI  
Date :12.02.2024